Commodities trader Glencore made a steady market debut with shares trading just above the widely expected launch price of 530 pence, giving it solid currency for potential acquisitions.
LinkedIn’s IPO, which is expected to price after the close of U.S. markets on Wednesday and start trading on Thursday, appears set to be a stunning success, but it carries a number of risks that may shake up investors in the future.
Commodities trader Glencore will close the books for its planned $11 billion initial public offering a day ahead of schedule, underscoring strong investor demand for its shares despite volatile commodity markets. A source told Reuters on Friday the offer was already “multiple times covered” across the price range, but part of that success is due to the relatively small stake in the company being placed with funds and to Glencore’s size, which makes it a must-buy for many.
Takeda Pharmaceutical is in talks to buy privately-held Swiss rival Nycomed for more than $12 billion, said sources with direct knowledge of the matter. Japan’s largest drugmaker is seeking to boost its presence in Europe and emerging markets, as well, the acquisition would help them gain a lung disease drug from Nycomed which has just been approved in the U.S. Japanese drugmakers have been actively pursuing acquisitions to boost growth as they face the loss of patent protection on key medicines.